X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Juventas states that the funds will be used to pursue a new drug application in China and launch implementation of a commercialization and international research and development plan for CNCT19.
Lead Product(s): CNCT19
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CICC Capital
Deal Size: $63.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing October 25, 2021
Details:
Juventas has initiated and enrolled the first patient in a Phase II registration study for CNCT19 (CD19 CAR-T) in China in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).
Lead Product(s): CNCT19
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $65.0 million Upfront Cash: Undisclosed
Deal Type: Financing November 18, 2020
Details:
With the restructuring in place, Juventas now can attract new capital to help fund its upcoming trials and build out a world-class GMP manufacturing facility for commercial production of CNCT19.
Lead Product(s): CNCT19
Therapeutic Area: Oncology Product Name: CNCT19
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
